ProPhase Labs, Inc. (PRPH) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PRPH Revenue Growth
Revenue Breakdown (FY 2024)
PRPH's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
PRPH Revenue Analysis (2013–2024)
As of May 8, 2026, ProPhase Labs, Inc. (PRPH) generated trailing twelve-month (TTM) revenue of $1.1 million, reflecting significant decline in growth of -71.9% year-over-year. The most recent quarter (Q3 2025) recorded $883,000 in revenue, down 29.2% sequentially.
Looking at the longer-term picture, PRPH's 5-year compound annual growth rate (CAGR) stands at -7.3%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $122.6 million in 2022.
Revenue diversification analysis shows PRPH's business is primarily driven by Consumer Products (100%). With over half of revenue concentrated in Consumer Products, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including QDEL (-3.9% YoY), CLOV (+48.7% YoY), and BNGO (-7.4% YoY), PRPH has underperformed the peer group in terms of revenue growth. Compare PRPH vs QDEL →
PRPH Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PRPHCurrent | $1M | -71.9% | -7.3% | -570.6% | |
 QDEL | $2.7B | -3.9% | +10.4% | -33.7% | |
 CLOV | $1.9B | +48.7% | +23.4% | -4.4% | |
 BNGO | $29M | -7.4% | +27.4% | -116.9% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% |
PRPH Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $6.8M | -84.7% | $-150,000 | -2.2% | $-38,629,000 | -570.6% |
| 2023 | $44.4M | -63.8% | $16.2M | 36.6% | $-21,613,000 | -48.7% |
| 2022 | $122.6M | +55.2% | $70.7M | 57.6% | $23.6M | 19.2% |
| 2021 | $79.0M | +444.6% | $32.8M | 41.5% | $9.8M | 12.4% |
| 2020 | $14.5M | +47.0% | $4.6M | 31.7% | $-3,973,000 | -27.4% |
| 2019 | $9.9M | -24.8% | $2.6M | 26.5% | $-3,239,000 | -32.8% |
| 2018 | $13.1M | +33.0% | $4.8M | 36.4% | $-1,634,000 | -12.4% |
| 2017 | $9.9M | -53.0% | $1.9M | 19.7% | $-3,990,000 | -40.4% |
| 2016 | $21.0M | +2.0% | $10.1M | 47.9% | $-2,656,000 | -12.6% |
| 2015 | $20.6M | -6.6% | $12.2M | 59.1% | $-3,584,000 | -17.4% |
See PRPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPRPH — Frequently Asked Questions
Quick answers to the most common questions about buying PRPH stock.
Is PRPH's revenue growth accelerating or slowing?
PRPH revenue declined -71.9% year-over-year, contrasting with the 5-year CAGR of -7.3%. TTM revenue fell to $1M. This reverses the prior growth trend.
What is PRPH's long-term revenue growth rate?
ProPhase Labs, Inc.'s 5-year revenue CAGR of -7.3% reflects the variable expansion pattern. Current YoY growth of -71.9% is below this long-term average.
How is PRPH's revenue distributed by segment?
PRPH reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.